This article presents a recommended Antiviral Target Compound Profile (TCP) developed by the INTREPID Alliance. The TCP is designed to accelerate the development of and facilitate global access to antivirals targeting pandemic-potential pathogens.
NIAID seeks proposals to advance the research and development of innovative candidate therapeutics, vaccines, and diagnostics for antimicrobial-resistant (AMR) pathogens and viruses with pandemic potential.
Renowned experts in virology, immunology, and drug development will help guide INTREPID’s efforts to accelerate breakthrough antiviral therapies for emerging viral pandemic agents
Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks
Detailed scientific analysis of antiviral pipeline identifies most promising clinical compounds aligned with 100 Days Mission global preparedness recommendations
The Chair of the INTREPID Alliance’s Scientific Advisory Board, Dr. Ruxandra Draghia-Akli, delivered remarks at the opening session of the International Arbovirus Summit hosted by GISAID and the Ministries of Health for Brazil and Indonesia.
Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts
As leaders and health experts from across the world gather in New York for the UN General Assembly, they will be considering three issues that are critical to the future of global health and global health security.
The INTREPID Alliance has abandoned its fundraising plans, but not its mission to expedite antiviral development for future pandemics.
An alliance of seven R&D-based pharma firms is putting collaboration and partnerships at the center of the search for new antivirals against emerging pathogens.
Seven innovative pharmaceutical companies have established the INTREPID Alliance, with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics.